News | January 25, 2024
Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Subscribe To Our Newsletter & Stay Updated
